Denmark-based biotech company QuantiBact A/S appoints Søren Morgenthaler Echwald as the company’s new CEO and renames the company to Anapa Biotech. The changes mark an important milestone in the company’s evolution.
QuantiBact/Anapa Biotech, a Danish biotech company founded in 2002 in microbiology and quantification of bacteria, has made significant developments during the past years shaping its technologies to improve genomic applications for diagnostics and life sciences.
To accelerate future development, Søren Morgenthaler Echwald is appointed new CEO and will be heading Anapa Biotech in the process towards commercialization of the company’s technologies. He comes from a position as VP business Development at Exiqon A/S, a leading supplier of high-value gene expression analysis products. Søren Echwald follows Palle Schelde who is leaving for a new job in the biotech industry.
Commercialization through partnering
“Palle Schelde has contributed significantly to the development during the past 3 years bringing Anapa Biotech’s platform to the first commercial agreements with our global distributor TriLink BioTechnologies Inc. and Eurofins MWG Operon. I am happy to announce the appointment of Søren Echwald to head Anapa Biotech’s next steps of the journey. Søren brings along valuable experience in bringing early stage technology to commercialization through partnering. His experience and competencies perfectly match Anapa Biotech’s strategy to grow partnerships with international companies within the diagnostics and Life Science industries,” says Patrik Dahlen, Chairman of Anapa Biotech’s Board of Directors.
“Anapa Biotech holds both unique technologies and strong IP and I look forward to further develop and explore the commercial potential,” says Søren M. Echwald.
Improving nature’s blueprint
The decision to change the company name from QuantiBact to Anapa Biotech has been made to mark the sharpened strategic focus. The company’s first commercially available technology, the TINA molecules are intercalators enhancing the performance of natural nucleic acids in PCR based assays as well as hybridization.
Anapa Biotech’s main investor is Vecata Invest A/S – an investment company managing the Bagger-Sorensen Group's investments in the venture segment.
“As the main shareholder, we hold strong expectations to the Anapa technology,” says John Riis Mortensen, Investment Director at Vecata Invest A/S. “With a new CEO in place, and sharpened focus and supported by strong applications, we look forward to advancing the Anapa Biotech technologies further in the years to come.”
Søren Morgenthaler Echwald, CEO, MSc, PhD
Anapa Biotech A/S,
Kettegaard Allé 30, 2650 Hvidovre, Denmark
Direct: +45 2264 4916
About Anapa Biotech
Anapa Biotech A/S, former QuantiBact A/S, develops molecular tools to enhance the performance of natural nucleic acids in PCR based assays as well as hybridization. Our technology offers improvement to areas like human and veterinary diagnostics, food and feed quality and safety, environmental surveillance and general scientific research. For more information, visit the new website at www.anapabiotech.com.
Vecata Invest A/S is an investment company managing the venture investments of the Bagger-Sorensen Group. The company invests primarily in Life Science, IT, and technology companies. For more information, visit their website at www.vecata.com.